Back to search

Article

CTLA-4 inhibitors drive colitis through metabolic reprogramming-mediated Treg/Th17 imbalance

2026-01-21

Abstract excerpt

Immune checkpoint inhibitors (ICIs), especially CTLA-4 inhibitors (αCTLA-4), exhibit a high incidence of colitis as an immune-related adverse event (irAE) during cancer treatment, severely limiting patient benefit. Clinically, both treatment interruption and existing intervention drugs for ICI-mediated colitis may compromise antitumor efficacy. However, there is inadequate research on the pathogenesis of ICI-media...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1f16aae2-0ade-536c-9efa-999a1a65f1c8
DOI
10.64898/2026.01.20.700699
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
CTLA-4 inhibitors drive colitis through metabolic reprogramming-mediated Treg/Th17 imbalanceDOI 10.64898/2026.01.20.700699
Select a neighboring publication to make it the new centre.